=> back to Techrights (Main Index)
00:08 *You are now known as schestowitz
00:54 schestowitz; http://ipkitten.blogspot.com/2023/08/make-no-bones-about-it-credibility-test.html?showComment=1694103240953#c6519183139123958630
00:54 schestowitz; "Kant, you make an excellent point, but I remind you of T2003/08, which 'stretched' a Swiss-style medical use claim to cover use of particular column to treat a patients plasma outside the body. See the relevant claim below: 1. Use of a specific ligand for human immunoglobulin in the manufacture of a column having said ligand coupled thereto for the treatment of a patient suffering from dilated cardiomyopathy, said tre
00:54 schestowitz; atment comprising passing plasma of the patient over the column under conditions which effect the binding of said specific ligand to immunoglobulin in the patient's plasma, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and reinfusing the plasma to the patient. [Also discussed in old IPKat article here https://ipkitten.blogspot.com/2014/05/swiss-type-claims-and-double-patenting.htm
=> ↺ https://ipkitten.blogspot.com/2014/05/swiss-type-claims-and-double-patenting.htm
00:54 schestowitz; l]So my belief is that the substance does not need to provide the therapeutic effect. Only the medical method as a whole needs to do that as recited in the claim. I believe T1020/03 established that ANY method of treatment can be expressed as an allowable medical use claim if a substance is somehow involved. The in vivo diagnostics case law for contrast agents for use in MRI also supports this approach with the invention oft
00:54 schestowitz; en being in the MRI method, and not in a new contrast agent."
00:54 -TechBytesBot/#techbytes-ipkitten.blogspot.com | Make no bones about it: The "credibility test" has no place in the novelty assessment of second medical use claims (T 0558/20) - The IPKat
00:54 -TechBytesBot/#techbytes- ( status 404 @ https://ipkitten.blogspot.com/2014/05/swiss-type-claims-and-double-patenting.htm )
=> ↺ https://ipkitten.blogspot.com/2014/05/swiss-type-claims-and-double-patenting.htm
00:55 schestowitz; "The adaptation of the description is not the subject of this post and I agree there is no reason to discuss this issue now. I am only surprised that you call it an old story since a referral to the EBA is suggested by the Board of case T 56/21. If it happens, the issue will be a very hot topic again and there will be ample opportunity for debates.From the Boards communication of June suggesting the referral, I take this
00:55 schestowitz; robust policy statement : It is not for the Office to harmonise the extent of protection conferred by European patents (and applications) by bringing the description and/or the drawings the amended claims held allowable. (Reason 3.2.3)."
00:55 schestowitz; "Mr. Thomas, for your reference, CIPA and CNIPA are not the same body. CNIPA was the "Committee of National Institutes of Patent Agents", a loose association of European patent bar associations, such as CIPA, PAK etc."
01:46 *jacobk has quit (Ping timeout: 2m30s)
03:15 *jacobk (~quassel@8cgmbeq9ipg9s.irc) has joined #techbytes
03:18 *MinceR gives voice to jacobk
05:24 *jacobk has quit (Ping timeout: 2m30s)
05:31 *jacobk (~quassel@8cgmbeq9ipg9s.irc) has joined #techbytes
06:27 *jacobk has quit (Ping timeout: 2m30s)
07:25 *jacobk (~quassel@32hz32it3ih2k.irc) has joined #techbytes
09:38 *u-amarsh04 has quit (Quit: Konversation terminated!)
09:42 *u-amarsh04 (~amarsh04@tqmhqqifyxsti.irc) has joined #techbytes
13:14 *MinceR gives voice to u-amarsh04 jacobk
13:18 *jacobk has quit (Ping timeout: 2m30s)
22:13 *XFaCE has quit (Quit: Retiring completely for now ("Automatic for the people, thanks for all the fish"))
22:14 *Noisytoot has quit (Quit: ZNC 1.8.2 - https://znc.in)
22:15 *XFaCE (~XFaCE@uzfeivw9fp6ba.irc) has joined #techbytes
22:16 *Noisytoot (~noisytoot@tkbibjhmbkvb8.irc) has joined #techbytes
22:16 *MinceR gives voice to XFaCE Noisytoot
22:20 *liberty_box has quit (Quit: Leaving)
=> back to Techrights (Main Index) This content has been proxied by September (ba2dc).Proxy Information
text/gemini;lang=en-GB